DelveInsight has launched a new report on Fabry Disease Market
The Fabry Disease market report provides an edge while developing business strategies, by understanding trends shaping and driving the Fabry Disease market report.
Fabry Disease Overview
Fabry disease (FD) is a devastating, progressive, inherited condition caused by lysosomal dysfunction linked to chromosome X and mutations in the GLA gene located in chromosome Xq22.1 which encodes the alpha-galactosidase A (AGA) enzyme.
Request for free sample copy- https://www.delveinsight.com/sample-request/fabry-disease-market
Regions Covered
Fabry Disease Treatment Market
The primary disease process starts in infancy, or even as early as in the fetal stage of development. In FD, lysosomal storage and cellular dysfunction are believed to trigger a cascade of events including cellular death, compromised energy metabolism, small vessel injury, K(Ca) channel dysfunction in endothelial cells, oxidative stress, impaired autophagosome maturation, tissue ischemia and, importantly, development of irreversible cardiac and renal tissue fibrosis.
Fabry Disease Market Disease
Fabry Disease is classified as the Type 1 classic and Type 2 later-onset on the basis of phenotype of the disease. Both sub-types result in renal failure, and/or cardiac disease, and early death. Type 2 later-onset Fabry Disease is more frequent as compared to Type 1 classic Fabry Disease.
Fabry Disease Market Companies
Fabry Disease Market Report
As per DelveInsight assessments, the market size of Fabry disease (FD) in the 7MM was found to USD 833.74 Million in 2017, for the study period (2017-2030). Among 7MM, United States accounts for the highest market size of Fabry disease in comparison with EU5 and Japan.
Fabry Disease Market Drugs
Currently, the therapeutic market size of Fabry disease is mainly accounted by Enzyme Replacement Therapy including (Fabrazyme, Replagal) and Chemical Chaperone Therapy (Migalastat, Amigal) are commonly used interventions. Moreover, symptomatic pain therapy for chronic neuropathic pain including Carbamazepine, Gabapentin, Phenytoin, Pregabalin, Tricyclic antidepressants, Duloxetine, Venlafaxine and for acute pain, the therapies including Intravenous lidocaine, Tramadol, Morphine, Oxycodone, Ibuprofen, Diclofenac) are in extensive use in the US market.
Fabry Disease Market Report Scope
Request for a free sample copy- https://www.delveinsight.com/sample-request/fabry-disease-market
Table of content
What will be the Key Questions Answered?
Reasons to buy
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: +919650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/